Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases. Our novel gene correction approach, called homology-directed repair (HDR), overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies. Our platform aims treat or cure a range of serious genetic diseases with unmet medical needs.
Industry
Biotechnology Research
HQ Location
South San Francisco, California 94080, US
Expertise
High efficiency targeted gene integrationHomology-directed repair (HDR)Gene editingClinical-stage biotechnology research
Solutions
Next-generation gene correction therapiesOne-time curative cell therapiesNovel gene correction approach (HDR)
Keywords
Biotechnology and Cell and Gene Therapy